Document Detail

Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery.
MedLine Citation:
PMID:  19802659     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Hip fracture surgery (HFS) carries a high risk of venous thromboembolism (VTE) in the absence of thromboprophylactic treatment. Previous reports have suggested that fondaparinux sodium (FPX) administration decreases the incidence of VTE after HFS and total hip and knee arthroplasties. However, investigations of that effect in Japanese populations remain inadequate. We evaluated the efficacy of FPX after HFS in a prospective randomized controlled trial. METHODS: Subjects comprised 76 consecutive Japanese patients who underwent HFS and were randomly assigned to the FPX group, who received subcutaneous injections of FPX 2.5 mg/day for 14 days beginning the next after HFS, or the control group (non-FPX group). D-dimer values were measured on admission and 7 and 14 days after HFS. Subjects with D-dimer levels over the cutoff value (> 20 microg/ml on day 7) underwent enhanced computed tomography (CT) to evaluate the possibility of deep vein thrombosis (DVT) of the lower extremities. D-dimer values, the incidence of DVT, and side effects associated with a bleeding tendency (i.e., hematoma or massive bleeding) were compared between groups. RESULTS: The FPX group showed significantly lower D-dimer levels than the non-FPX group at 7 and 14 days after HFS (P < 0.05). Only one case in the FPX group exceeded the D-dimer cutoff compared to 12 cases in the non-FPX group (P = 0.001). DVTs were found with enhanced CT in one case in the FPX group and in five cases in the non-FPX group. In the FPX group, symptomatic hematoma at the surgical site and/or decreased hemoglobin > 2 g/dl was noted in four cases (10.5%). Postoperative drainage volumes did not differ significantly between groups. CONCLUSIONS: FPX administration demonstrated positive effects on the prevention of VTE after HFS. However, careful postoperative observation is warranted to prevent serious side effects after FPX administration.
Satoshi Sasaki; Naohisa Miyakoshi; Hiroshi Matsuura; Hidetomo Saitoh; Daisuke Kudoh; Yoichi Shimada
Related Documents :
10505539 - Design, baseline characteristics, and preliminary clinical results of the organization ...
1621199 - A prospective study on intermittent pneumatic compression in the prevention of deep vei...
9200339 - Prolonged prophylaxis in postoperative medicine.
17449089 - Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review.
19020209 - Transcatheter arterial embolization in the emergency department for hemodynamic instabi...
7368149 - Low dose heparin in the prevention of deep-vein thrombosis after aortic bifurcation gra...
2368879 - Selective or total shunts for variceal bleeding.
19456829 - Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immu...
24403349 - Does single ventricle physiology affect survival of children requiring extracorporeal m...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2009-10-03
Journal Detail:
Title:  Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association     Volume:  14     ISSN:  1436-2023     ISO Abbreviation:  J Orthop Sci     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-10-05     Completed Date:  2010-01-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9604934     Medline TA:  J Orthop Sci     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  491-6     Citation Subset:  IM    
Department of Orthopedic Surgery, Yuri-Kumiai General Hospital, Yuri-Honjo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anticoagulants / therapeutic use*
Fibrin Fibrinogen Degradation Products / analysis*
Fracture Fixation / adverse effects*
Hip Fractures / surgery*
Polysaccharides / therapeutic use*
Venous Thromboembolism / etiology,  prevention & control*
Venous Thrombosis / etiology,  prevention & control
Reg. No./Substance:
0/Anticoagulants; 0/Fibrin Fibrinogen Degradation Products; 0/Polysaccharides; 0/fibrin fragment D; 0/fondaparinux

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessment of thrombotic risk factors predisposing to thromboembolic complications in prosthetic ort...
Next Document:  How accurate is image-free computer navigation for hip resurfacing arthroplasty? An anatomical inves...